Abstract | Background: The advantages of nanomedicines include preferential delivery of the payload directly to tumor tissues. CYT-21625 is the novel, first-in-class gold nanomedicine designed to target tumor vasculature and cancer cells by specifically delivering recombinant human tumor necrosis factor alpha (rhTNF) and a paclitaxel prodrug. Methods: We analyzed TNF receptor expression in publicly available gene expression profiling data and in thyroid tissue samples. Mice with metastatic FTC-133 and 8505C xenografts and the MEN1 conditional knock-out mice were treated weekly with CYT-21625 and gold nanoparticles with rhTNF only (CYT-6091); controls included mice treated with either paclitaxel or saline. In vivo luciferase activity was used to assess the effects on tumor growth. Computed tomography, magnetic resonance imaging, and 18F-Fludeoxyglucose positron emission tomography were used to study tumor selectivity in mice with insulin-secreting pancreatic neuroendocrine tumors ( PNETs). All statistical tests were two-sided. Results:
Anaplastic thyroid cancer (ATC) expressed statistically significantly higher levels of TNF receptor superfamily 1A and 1B messenger RNA (n = 11) and protein (n = 6) than control samples (n = 45 and 13, respectively). Mice (n = 5-7 per group) with metastatic ATC (P < .009) and FTC-133 xenografts (P = .03 at week 3, but not statistically significant in week 4 owing to reduced sample size from death in non-CYT-21625 groups) treated with CYT-21625 had a statistically significantly lower tumor burden. Treatment with CYT-21625 resulted in loss of CD34 expression in intratumoral vasculature, decreased proliferating cell nuclear antigen, and increased cleaved caspase-3. Intratumoral vascular leakage occurred only in mice with PNET and ATC treated with CYT-6091 and CYT-21625. CYT-6091 and CYT-21625 preferentially deposited in PNETs and statistically significantly decreased serum insulin levels (n = 3 per group, P < .001). There were no toxicities observed in mice treated with CYT-21625. Conclusions:
|
Authors | Naris Nilubol, ZiQiang Yuan, Giulio F Paciotti, Lawrence Tamarkin, Carmen Sanchez, Kelli Gaskins, Esther M Freedman, Shugeng Cao, Jielu Zhao, David G I Kingston, Steven K Libutti, Electron Kebebew |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 110
Issue 9
Pg. 1019-1029
(09 01 2018)
ISSN: 1460-2105 [Electronic] United States |
PMID | 29481652
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- CYT-6091
- Recombinant Proteins
- Tumor Necrosis Factor-alpha
- Polyethylene Glycols
- Gold
|
Topics |
- Animals
- Capillary Permeability
(drug effects)
- Cell Line, Tumor
- Disease Models, Animal
- Endothelium, Vascular
(drug effects, metabolism)
- Gene Expression
- Gene Expression Profiling
- Gold
(pharmacology)
- Humans
- Mice
- Mice, Knockout
- Molecular Targeted Therapy
- Neoplasm Grading
- Neoplasm Metastasis
- Neoplasm Staging
- Neovascularization, Pathologic
(therapy)
- Neuroendocrine Tumors
(genetics, pathology, therapy)
- Pancreatic Neoplasms
(genetics, pathology, therapy)
- Polyethylene Glycols
(pharmacology)
- Recombinant Proteins
- Theranostic Nanomedicine
- Thyroid Neoplasms
(genetics, pathology, therapy)
- Tumor Necrosis Factor-alpha
(pharmacology, therapeutic use)
- Xenograft Model Antitumor Assays
|